Elsevier

Cellular Immunology

Volume 298, Issues 1–2, November–December 2015, Pages 25-32
Cellular Immunology

Review article
Functional roles of HIV-1 Vpu and CD74: Details and implications of the Vpu–CD74 interaction

https://doi.org/10.1016/j.cellimm.2015.08.005Get rights and content

Highlights

  • Vpu is an important accessory protein of HIV-1 that is found in a few SIV isolates, but not in HIV-2 and has many important functions that assist in disease progression.

  • Virus isolates that do not contain a fully functional Vpu protein have less severity in disease outcome, highlighting the importance of this protein for HIV-1 persistence.

  • Human CD74 plays a role in a variety of important functions within the cell including antigen presentation through chaperoning MHCII for immune activation and cell signaling through binding MIF. CD74 is also involved in B cell proliferation and maturation.

  • Vpu and CD74 interact via their cytoplasmic domains within the ER resulting in the downregulation of MHCII and decrease in antigen presentation, ultimately affecting immune activation.

  • The Vpu–CD74 interaction is a viable drug target. Inhibition of this interaction may be advantageous to the infected host as unbound CD74 would be able to continue its important functions within the broad spectrum of the immune system.

Abstract

HIV-1 Vpu has a variety of functions, including CD4 degradation and the downregulation of MHCII. Downregulation of the MHCII occurs through Vpu binding to the cytoplasmic domain of CD74, the chaperone for antigen presentation. The CD74 cytoplasmic domain also plays a vital role in cell signaling through the activation of an NF-κB signal cascade for the maturation, proliferation and survival of B cells as well as by binding the macrophage inhibitory factor. In view of these functions, it follows that the Vpu–CD74 interaction has multiple downstream consequences for the immune system as it not only impairs foreign antigen presentation but may also have an effect on signal transduction cascades. It is thought that Vpu specifically targets intracellular CD74 while other HIV-1 proteins cannot. Therefore, this protein–protein interaction would be a potential drug target in order to reduce viral persistence. We review the functional importance and specific binding site of Vpu and CD74.

Introduction

HIV-1 has several accessory genes, namely vif, vpr, nef and vpu. The accessory proteins encoded by these genes play important roles in viral replication [1]. Vif targets the host restriction factor APOBEC3G for proteasomal degradation to prevent the inhibition of viral DNA synthesis [2], [3], [4]. Vpr has many functions including activation of cell death and proviral transcription [4], [5]. Nef is a functionally diverse protein that is involved in the alteration of cell signaling pathways, disruption of antigen presentation by MHCI and MHCII and alteration of gene and receptor surface expression [4], [6]. Lastly, Vpu also has multiple functions within the host cell, some of which are similar to Nef, with the most well-described functions being the degradation of the HIV-1 receptor CD4 and virion release [4], [7], [8].

Of particular interest, Vpu is only encoded by the genome of HIV-1 and a few simian immunodeficiency virus (SIV) isolates such as SIVcpz (chimpanzee), SIVmon (mona monkey), SIVgsn (greater spot-nosed monkey), SIVmus (mustached monkey) and SIVden (Dent’s mona monkey), but is not found within HIV-2 [9]. Related isolates that do not express a functional Vpu protein have far less severity in terms of disease outcome [10] indicating the importance of this viral protein. HIV-1 infections tend to result in chronic immune activation, while HIV-2 infections yield lower levels of immune activation [11] and SIVs of sooty mangabeys and African green monkeys, which do not encode vpu, generally also do not cause high levels of immune activation [12]. Furthermore, the functionality of the Vpu protein in the HIV-1 strains of M, N and O has been suggested to be necessary for the spread of the pandemic M strain as this strain expresses a Vpu protein that is not only able to target CD4 for degradation, but also effectively antagonizes tetherin [4], [9]. The non-pandemic N and O strains express a Vpu protein that is lacking in one of the primary functions. Although HIV-2 targets tetherin using the Env protein, this has been found to be less effective than that of HIV-1 Vpu [9]. HIV-1 Vpu appears to target the immune system in many different but related ways that are highly effective at sabotaging the immune response and that work in conjunction with other HIV-1 proteins to more effectively enhance viral replication. As each component of the immune system that is targeted by Vpu is important, the impairment of Vpu function would likely increase the ability of the immune system to respond to HIV-1 infection.

One of the more recently described functions of Vpu is the downregulation of the MHCII, specifically through the interaction with the MHCII-associated invariant chain, or CD74 [13]. As CD74 plays a role in many important cellular functions, including the immune response, it is feasible that the binding of Vpu to this host protein has multiple downstream consequences for the immune response apart from the downregulation of the MHCII. Therefore downregulation of this host protein is beneficial for viral persistence. In this review, we take a look at the multiple functions of both Vpu and CD74 within the infected cell and examine the specific interaction and binding site between these two proteins and consider the possible ramifications of this interaction. Finally, we contemplate on the suitability of this protein–protein interaction as a possible novel therapeutic target for drug intervention.

Section snippets

HIV-1 Vpu structure

Vpu is an 81-mer type I integral intracellular membrane protein that is expressed in the later stages of viral infection. Vpu has an N-terminal transmembrane hydrophobic helix (residues 1–27) and two amphipathic helices (residues 35–50 and 58–70) that form part of the cytoplasmic domain and are separated by a linker region (residues 47–58) [14], [15], [16]. The linker region has two highly conserved serine residues in the cytoplasmic domain, namely Ser52 and Ser56 [16] that are required for the

HIV-1 Vpu functions

The two primary functions of Vpu are the degradation of CD4, the primary receptor protein for HIV-1 [23], [24], [25] and the release of new virus particles from infected cells either by inhibition of the host restriction factor, tetherin [26], [27], [28], [29] or through the viroporin activity of Vpu in which the transmembrane domain is able to form an ion channel in a separate mechanism to that of the antagonism of tetherin [30], [31], [32]. Vpu also seems to undermine or impair the immune

Human CD74 structure

CD74 consists of a 30-mer N-terminal cytoplasmic domain, a 26-mer transmembrane domain and a 160 amino acid sequence that is either extracellular or projects into the lumen, depending on the subcellular location of the protein [13]. There are several isoforms of CD74, namely p33, p35, p41 and p43 [61]. Ii-p33 and Ii-p35 are 33 kDa and 35 kDa, respectively and are involved in MHCII antigen presentation with the Ii-p33 isoform being the prominent of the two. These isoforms originate in two ways,

Human CD74 functions

One of the most well described functions of CD74 is its role in antigen presentation through association with the MHCII complex [53], [55], [56]. However, the expression of CD74 is separate to that of the MHCII molecules and this allows CD74 to have numerous other functions within the cells. During cleavage of CD74 within the endosome, a portion of the CD74-ICD translocates to the cell nucleus (Fig. 1A) and thereby initiates a signal cascade by activating the phosphatidylinositol 3′-kinase, Syk

Interaction between Vpu and CD74

Vpu and CD74 were found to interact via their cytoplasmic domains within the ER [13], similar to that of the Vpu–CD4 interaction [7]. Specific sequences in the cytoplasmic domain of Vpu were identified to be necessary to induce the degradation of CD4 [24], [84]. The CD4 binding site on Vpu overlaps with the immunodominant domain, as CD4 prevents the binding of antibodies directed against the Vpu cytoplasmic domain [7], [85]. In a similar study, it was also shown that an antibody directed

Targeting of the Vpu/CD74 interaction

Vpu is able to connect viral and host cellular proteins to cellular pathways, as well as regulate these pathways through protein–protein interactions in order to promote viral replication [23], making this protein actively involved in the establishment of infective persistence within the host. As previously mentioned, HIV or SIV isolates that do not express a functional Vpu protein have less severity in terms of disease outcome [10]. Therefore targeting the interactions of this particular

Conclusions

As both HIV-1 Vpu and the host protein CD74 have a wide variety of functions, inhibition of the interaction between these two proteins may be highly disadvantageous for viral persistence. While this interaction is easily assayable and monitored in vitro, the lack of a three dimensional structure for CD74 may delay the rational design of novel inhibitors for the specific binding site between CD74 and Vpu. Despite this the Vpu–CD74 interaction is still a viable drug target as Vpu targets

Funding source contributions

The above mentioned funding sources had no involvement in the research and preparation of this article.

Author contributions

D.L. – conceptual idea as well as writing of the review.

R.H. – conceptual idea, critical revision and final approval of submitted manuscript.

S.M. – conceptual idea, critical revision and final approval of submitted manuscript.

M.P. – conceptual idea, critical revision and final approval of submitted manuscript.

Acknowledgments

The authors wish to acknowledge Mintek and the University of the Witwatersrand for funding this research as well as the National Research Foundation for awarding the Professional Development Programme grant to the first author to conduct the research. The authors also wish to acknowledge Martine Whitehead for her expertise in the graphical design of the schematics.

References (88)

  • C.T. Weaver et al.

    Th17: an effector of CD4 T cell lineage with regulatory T cell ties

    Immunity

    (2006)
  • J. Zhu et al.

    CD4 T cells: fates, functions, and faults

    Blood

    (2008)
  • F. Margottin et al.

    A novel human WD protein h-BTrCP, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif

    Mol. Cell

    (1998)
  • P.B. Moore et al.

    Simulation of the HIV-1 Vpu transmembrane domain as a pentameric bundle

    FEBS Lett.

    (1998)
  • S. Bour et al.

    The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release

    Microbes Infect.

    (2003)
  • A.L. Grice et al.

    Ion channels formed by HIV-1 Vpu: a modelling and simulation study

    FEBS Lett.

    (1997)
  • K. Muthumani et al.

    HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells

    J. Biol. Chem.

    (2002)
  • V.B. Peters et al.

    The effect of viruses on the ability to present antigens via the major histocompatibility complex

    Microbes Infect.

    (1999)
  • M. Robertson

    Antigen presentation

    Curr. Biol.

    (1998)
  • D.M. Miller et al.

    Viral effects on antigen processing

    Curr. Opin. Immunol.

    (1999)
  • Y. Ghiglione et al.

    HIV-mediated up-regulation of invariant chain (CD74) correlates with generalized immune activation in HIV+ subjects

    Virus Res.

    (2012)
  • A. Motta et al.

    Structure–activity relationship of the leucine-based sorting motifs in the cytosolic tail of the major histocompatibility complex-associated invariant chain

    J. Biol. Chem.

    (1995)
  • S. Kang et al.

    Structural requirements for major histocompatibility complex class II invariant chain endocytosis and lysosomal targeting

    J. Biol. Chem.

    (1998)
  • A. Schlundt et al.

    Peptide linkage to the α-subunit of MHCII creates a stably inverted antigen presentation complex

    J. Mol. Biol.

    (2012)
  • D. Matza et al.

    Invariant chain induces B cell maturation by activating a TAFII105-NF-κB-dependent transcription program

    J. Biol. Chem.

    (2001)
  • D. Starlets et al.

    Cell-surface CD74 initiates a signalling cascade leading to cell proliferation and survival

    Blood

    (2006)
  • F. Lantner et al.

    CD74 induces TAp63 expression leading to B-cell survival

    Blood

    (2007)
  • D. Matza et al.

    Invariant chain-induced B cell differentiation requires intramembrane proteolytic release of the cytosolic domain

    Immunity

    (2002)
  • S. Ishigami et al.

    Invariant chain expression in gastric cancer

    Cancer Lett.

    (2001)
  • S. Bour et al.

    The human immunodeficiency virus type 1 Vpu protein inhibits NF-kB activation by interfering with BTrCP-mediated degradation of IkB

    J. Biol. Chem.

    (2001)
  • F. Margottin et al.

    Interaction between the cytoplasmic domains of HIV-1 Vpu and CD4: role of Vpu residues involved in CD4 interaction and in vitro CD4 degradation

    Virology

    (1996)
  • D.R. Hout et al.

    A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian-human immunodeficiency virus (SHIVKU-1bMC33) susceptible to rimantadine

    Virology

    (2006)
  • F.M. Marassi et al.

    Correlation of the structural and functional domains in the membrane protein Vpu from HIV-1

    Proc. Natl. Acad. Sci. U.S.A.

    (1999)
  • A.M. Sheehy et al.

    The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

    Nat. Med.

    (2003)
  • E. Miyagi et al.

    Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1

    J. Virol.

    (2007)
  • V. Planelles et al.

    Vpr and its interactions with cellular proteins

    Curr. Top. Microbiol. Immunol.

    (2009)
  • P. Stumptner-Cuvelette et al.

    HIV-1 Nef impairs MHC class II antigen presentation and surface expression

    Proc. Natl. Acad. Sci. U.S.A.

    (2001)
  • S. Bour et al.

    The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation

    J. Virol.

    (1995)
  • H.G. Göttlinger et al.

    Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses

    Proc. Natl. Acad. Sci. U.S.A.

    (1993)
  • M. Dube et al.

    Modulation of HIV-1–host interaction: role of the Vpu accessory protein

    Retrovirology

    (2010)
  • A. Leligdowicz et al.

    Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection

    Expert Rev. Vaccines

    (2008)
  • S. Nyamweya et al.

    Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis

    Rev. Med. Virol.

    (2013)
  • J.M. Brenchley et al.

    The mucosal barrier and immune activation in HIV pathogenesis

    Curr. Opin. HIV AIDS

    (2008)
  • A. Hussain et al.

    Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation

    J. Virol.

    (2008)
  • Cited by (0)

    1

    Present address: School of Biochemistry, Genetics and Microbiology, University of Kwa-Zulu Natal, Private Bag X01, Scottsville 3209, South Africa.

    View full text